Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Comparison of the effectiveness of antibody and cell-mediated immunity against inhaled and instilled influenza virus challenge.

Rivers K, Bowen LE, Gao J, Yang K, Trombley JE, Bohannon JK, Eichelberger MC.

Virol J. 2013 Jun 19;10:198. doi: 10.1186/1743-422X-10-198.

2.

Development of a murine nose-only inhalation model of influenza: comparison of disease caused by instilled and inhaled A/PR/8/34.

Bowen LE, Rivers K, Trombley JE, Bohannon JK, Li SX, Boydston JA, Eichelberger MC.

Front Cell Infect Microbiol. 2012 May 30;2:74. doi: 10.3389/fcimb.2012.00074. eCollection 2012.

3.

Intranasal immunization with liposome-encapsulated plasmid DNA encoding influenza virus hemagglutinin elicits mucosal, cellular and humoral immune responses.

Wang D, Christopher ME, Nagata LP, Zabielski MA, Li H, Wong JP, Samuel J.

J Clin Virol. 2004 Dec;31 Suppl 1:S99-106.

PMID:
15567101
4.

A DNA vaccine-encoded nucleoprotein of influenza virus fails to induce cellular immune responses in a diabetic mouse model.

Jamali A, Sabahi F, Bamdad T, Hashemi H, Mahboudi F, Kheiri MT.

Clin Vaccine Immunol. 2010 Apr;17(4):683-7. doi: 10.1128/CVI.00445-09. Epub 2010 Feb 17.

5.

Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutinin- and neuraminidase-expressing DNAs.

Chen Z, Matsuo K, Asanuma H, Takahashi H, Iwasaki T, Suzuki Y, Aizawa C, Kurata T, Tamura S.

Vaccine. 1999 Feb 26;17(7-8):653-9.

PMID:
10067670
6.

Antibody contributes to heterosubtypic protection against influenza A-induced tachypnea in cotton rats.

Straight TM, Ottolini MG, Prince GA, Eichelberger MC.

Virol J. 2008 Mar 20;5:44. doi: 10.1186/1743-422X-5-44.

7.

Heterosubtypic protective immunity against influenza A virus induced by fusion peptide of the hemagglutinin in comparison to ectodomain of M2 protein.

Staneková Z, Király J, Stropkovská A, Mikušková T, Mucha V, Kostolanský F, Varečková E.

Acta Virol. 2011;55(1):61-7.

PMID:
21434706
8.

Intranasal immunization of baculovirus displayed hemagglutinin confers complete protection against mouse adapted highly pathogenic H7N7 reassortant influenza virus.

Rajesh Kumar S, Syed Khader SM, Kiener TK, Szyporta M, Kwang J.

PLoS One. 2013 Jun 7;8(6):e63856. doi: 10.1371/journal.pone.0063856. Print 2013.

9.

Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in mice.

Huang B, Wang W, Li R, Wang X, Jiang T, Qi X, Gao Y, Tan W, Ruan L.

Virol J. 2012 Dec 29;9:322. doi: 10.1186/1743-422X-9-322.

10.

Co-administration of certain DNA vaccine combinations expressing different H5N1 influenza virus antigens can be beneficial or detrimental to immune protection.

Patel A, Gray M, Li Y, Kobasa D, Yao X, Kobinger GP.

Vaccine. 2012 Jan 11;30(3):626-36. doi: 10.1016/j.vaccine.2011.11.017. Epub 2011 Nov 23.

PMID:
22119588
11.

Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.

de Haan A, Haijema BJ, Voorn P, Meijerhof T, van Roosmalen ML, Leenhouts K.

Vaccine. 2012 Jul 6;30(32):4884-91. doi: 10.1016/j.vaccine.2012.04.032. Epub 2012 Apr 23.

PMID:
22537989
12.

Pre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutinin.

Alexander J, Ward S, Mendy J, Manayani DJ, Farness P, Avanzini JB, Guenther B, Garduno F, Jow L, Snarsky V, Ishioka G, Dong X, Vang L, Newman MJ, Mayall T.

PLoS One. 2012;7(2):e31177. doi: 10.1371/journal.pone.0031177. Epub 2012 Feb 17.

13.

Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses.

Altstein AD, Gitelman AK, Smirnov YA, Piskareva LM, Zakharova LG, Pashvykina GV, Shmarov MM, Zhirnov OP, Varich NP, Ilyinskii PO, Shneider AM.

Arch Virol. 2006 May;151(5):921-31. Epub 2005 Nov 15.

PMID:
16292596
14.

Cross-protection against influenza A virus infection by passively transferred respiratory tract IgA antibodies to different hemagglutinin molecules.

Tamura S, Funato H, Hirabayashi Y, Suzuki Y, Nagamine T, Aizawa C, Kurata T.

Eur J Immunol. 1991 Jun;21(6):1337-44.

PMID:
1646112
15.

Protection against influenza virus infection in mice immunized by administration of hemagglutinin-expressing DNAs with electroporation.

Kadowaki S, Chen Z, Asanuma H, Aizawa C, Kurata T, Tamura S.

Vaccine. 2000 Jun 15;18(25):2779-88.

PMID:
10812219
16.

Sublingual immunization with M2-based vaccine induces broad protective immunity against influenza.

Shim BS, Choi YK, Yun CH, Lee EG, Jeon YS, Park SM, Cheon IS, Joo DH, Cho CH, Song MS, Seo SU, Byun YH, Park HJ, Poo H, Seong BL, Kim JO, Nguyen HH, Stadler K, Kim DW, Hong KJ, Czerkinsky C, Song MK.

PLoS One. 2011;6(11):e27953. doi: 10.1371/journal.pone.0027953. Epub 2011 Nov 30.

17.

In contrast to conventional inactivated influenza vaccines, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran.

Ebrahimi SM, Dabaghian M, Tebianian M, Jazi MH.

Virology. 2012 Aug 15;430(1):63-72. doi: 10.1016/j.virol.2012.04.015. Epub 2012 May 16.

18.

A single immunization with HA DNA vaccine by electroporation induces early protection against H5N1 avian influenza virus challenge in mice.

Zheng L, Wang F, Yang Z, Chen J, Chang H, Chen Z.

BMC Infect Dis. 2009 Feb 12;9:17. doi: 10.1186/1471-2334-9-17.

19.

Induction of cross-protection against influenza A virus by DNA prime-intranasal protein boost strategy based on nucleoprotein.

Luo J, Zheng D, Zhang W, Fang F, Wang H, Sun Y, Ding Y, Xu C, Chen Q, Zhang H, Huang D, Sun B, Chen Z.

Virol J. 2012 Nov 23;9:286. doi: 10.1186/1743-422X-9-286.

20.

Heterosubtypic protection against influenza A induced by adenylate cyclase toxoids delivering conserved HA2 subunit of hemagglutinin.

Staneková Z, Adkins I, Kosová M, Janulíková J, Sebo P, Varečková E.

Antiviral Res. 2013 Jan;97(1):24-35. doi: 10.1016/j.antiviral.2012.09.008. Epub 2012 Oct 2.

PMID:
23036818

Supplemental Content

Support Center